A prospective study to evaluate the immune response of UK infants receiving the 13-valent pneumococcal conjugate vaccine as part of their routine primary immunisation schedule at 2 and 4 months (code: P13UK)

Trial Profile

A prospective study to evaluate the immune response of UK infants receiving the 13-valent pneumococcal conjugate vaccine as part of their routine primary immunisation schedule at 2 and 4 months (code: P13UK)

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Hib-DTaP-poliovirus vaccine; Meningococcal vaccine group C conjugate
  • Indications Diphtheria; Haemophilus infections; Meningococcal group C infections; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Sep 2011 Planned end date (1 Jun 2013) added as reported by ClinicalTrials.gov.
    • 01 Sep 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01425372).
    • 27 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top